Revolutionary Results: Vascepa/Vazkepa (Icosapent Ethyl) Reduces STEMI and Other MI Subtypes According to Latest IT Data
Late-breaking data presented at the European Society of Cardiology (ESC) Congress 2022 has revealed exciting findings regarding VASCEPA/VAZKEPA. According to the study, the use of VASCEPA/VAZKEPA resulted in a significant reduction of 40% in ST-elevation myocardial infarction (STEMI) and 27% in non-ST elevation myocardial infarction (NSTEMI) in pre-specified, post hoc analyses. This new data has…